RefleXion has secured an installation of its RefleXion X1 platform with Scintix biology-guided radiotherapy at a freestanding imaging center in California.
Beverly Hills Cancer Center is the first such center to install the device, according to the firm.
Scintix therapy uses signals emitted from cancer cells in response to a PET imaging tracer to direct radiation treatment, RefleXion said. Beginning in 2025, the Centers for Medicare and Medicaid Services (CMS) will expand reimbursement for Scintix therapy, introducing new billing codes for freestanding cancer centers and professional reimbursement for physicians in both freestanding cancer centers and hospital outpatient departments, the company noted.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
